Original from: genomeweb

Contract research organization Inotiv said Thursday that it has partnered with Lithuanian multiomics data analysis firm Vugene on artificial intelligence-assisted drug discovery. 

Under the terms of the deal, Inotiv, based in West Lafayette, Indiana, will integrate Vugene's bioinformatics and computational platform in hope of improving predictions of drug efficacy and safety in early-stage research. Vugene's platform analyzes and interprets a variety of data types including genomics, epigenomics, transcriptomics, proteomics, and metabolomics data. Vugene raised $1.1 million in May. 

Financial and other terms were not disclosed.

"To maximize the value of our clients’ discovery programs, we must efficiently integrate and interpret complex datasets," Scott Daniels, senior VP of drug discovery and translational sciences at Inotiv, said in a statement. "Vugene's AI-enabled bioinformatics platform gives our team a powerful tool to advance data-driven, AI-assisted discovery, helping clients make faster, more informed decisions."

Source: Inotiv, Vugene Partner on AI-Driven Drug Discovery Using Multiomics Data